A trial titled “PASADENA” enrolled a little over 300 participants with early Parkinson’s and compared two different doses of the drug against a placebo. Results from the study, which were ...

In the end, PNA5 might not curb all Parkinson's symptoms, but could be used alongside other meds. “I think about it as a cog in the wheel -- there are going to be other drugs that support other ...

So far, prasinezumab has yet to notch a clear victory in clinical testing. A trial titled “PASADENA” enrolled a little over 300 participants with early Parkinson’s and compared two different doses of ...

These drug candidates are high risk/high reward bets on the future of therapies in AL amyloidosis, Parkinson's disease, ATTR amyloidosis and Alzheimer's disease. The most advanced drug candidate ...

For the second time this week, a Big Pharma–partnered Parkinson’s disease asset has failed in the clinic. This time it’s Roche reporting that a drug under development with Prothena since 2013 was ...

Investing.com -- Roche's experimental Parkinson's disease drug, prasinezumab, failed to meet its primary objective in a mid-stage trial. The Swiss pharmaceutical giant announced on Thursday that ...